Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of apraglutide for long-term safety in short bowel syndrome with intestinal failure
MOH_2021-11-28_010429Phase 3Not yet recruiting
- Sponsor
- VectivBio
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS) and intestinal failure (IF), sponsored by VectivBio. Primary endpoint: Long-term safety and tolerability of apraglutide. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on MOH_2021-11-28_010429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-28_010429.